Key Findings from the NADINA Trial at ASCO 2024

Dr Lipson continues his discussion as he highlights significant results from the NADINA trial.

Video content above is prompted by the following:

  • Discuss the data presented at the 2024 ASCO Annual Meeting on the phase 3 NADINA trial (NCT04949113) of neoadjuvant nivolumab plus ipilimumab vs adjuvant nivolumab in patients with macroscopic, resectable stage III melanoma.
    • What was the objective of this study?
    • How was this study designed/what methodology was used?
    • What results were presented?
  • Please provide your key takeaways from this study. How might these findings impact the treatment of patients with melanoma?
  • What are the key considerations when deciding between neoadjuvant and adjuvant therapy for patients with resectable melanoma?
Related Videos
This series features 1 KOL.
A panel of 4 experts on chronic spontaneous urticaria
A panel of 4 experts on chronic spontaneous urticaria
1 KOL is featured in this series.
Related Content
CH LogoCenter for Biosimilars Logo